Extensor digitorum brevis test and resistance to botulinum toxin type A

We studied 22 patients with dystonia to determine the normal range of values for the extensor digitorum brevis (EDB) test, and to determine its sensitivity and specificity in detecting resistance to botulinum toxin type A (BTX‐A). Three compound muscle action potentials (CMAPs) elicited by peroneal nerve stimulation were averaged before and 2 weeks after injection of 20 units of BTX‐A into the EDB. Amplitude and area ratios were calculated by dividing the averaged postinjection CMAP by the averaged preinjection CMAP values. The difference in means of this ratio between clinically sensitive and resistant subjects was statistically significant (P < 0.002). A normal range of <0.45 for each ratio was determined by adding two standard deviations to the ratio mean of 14 clinically sensitive subjects. Four of five resistant patients had values outside the normal range. The EDB test is a simple quantitative method of detecting resistance to BTX‐A, with a sensitivity of 80% and specificity of 94%. © 2002 Wiley Periodicals, Inc. Muscle Nerve 26: 828–831, 2002

[1]  S Fahn,et al.  Development of resistance to botulinum toxin type A in patients with torticollis , 2004, Movement disorders : official journal of the Movement Disorder Society.

[2]  R. Richard Sloop,et al.  Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals , 2001, Movement disorders : official journal of the Movement Disorder Society.

[3]  J. Rothwell,et al.  The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans , 2000, Journal of Neurology.

[4]  A. Lees,et al.  Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A , 1998, Journal of neurology, neurosurgery, and psychiatry.

[5]  K. Wohlfarth,et al.  Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences , 1997, Experimental Neurology.

[6]  R. Sloop,et al.  Human response to botulinum toxin injection: Type B compared with type A , 1997, Neurology.

[7]  R. Sloop,et al.  Reconstituted Botulinum Toxin Type A Does Not Lose Potency in Humans If It Is Refrozen or Refrigerated for 2 Weeks Before Use , 1997, Neurology.

[8]  R. Benecke,et al.  The EDB Test—A clinical test for the detection of antibodies to botulinum toxin type A , 1997 .

[9]  G. Peterson,et al.  Dose‐response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A , 1996, Neurology.

[10]  K. Schwartz,et al.  Response and immunoresistance to botulinum toxin injections , 1995, Neurology.

[11]  F. Walker,et al.  Serial neurophysiological studies of intramuscular botulinum‐A toxin in humans , 1994, Muscle & nerve.

[12]  C. Hatheway,et al.  Immunogenicity of the neurotoxins of Clostridium botulinum , 1994 .

[13]  N. Bathien,et al.  Botulinum antibodies in dystonic patients treated with type A botulinum toxin , 1993, Neurology.

[14]  H E Cohen,et al.  Antitoxins and botulinum toxin treatment. , 1992, BMJ.

[15]  J. Jankovic,et al.  Therapeutic uses of botulinum toxin. , 1991, The New England journal of medicine.

[16]  E. Schantz,et al.  Dose standardisation of botulinum toxin , 1990, The Lancet.

[17]  L. S. Siegel,et al.  Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay , 1988, Journal of clinical microbiology.

[18]  D. Lison,et al.  Dose standardization of botulinum toxin. , 1998, Advances in neurology.

[19]  S. Fahn,et al.  Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A , 1993, Movement disorders : official journal of the Movement Disorder Society.

[20]  D. Kautter,et al.  Standardized assay for Clostridium botulinum toxins [in foods]. , 1978 .